Qiagen NV
Open
$37.07
Prev. Close
$37.06
High
$37.13
Low
$37.04
Market Snapshot
$8.04B
20.0
0.36
$1.98B
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Recently from Cashu

Qiagen Launches Digital PCR Assays to Combat Bundibugyo Ebolavirus and Enhance Diagnostics
In the face of ongoing infectious disease challenges, Qiagen NV (Ticker: QGEN) is making significant strides with the recent launch of research-use-only digital PCR assays aimed specifically at the Bu…

Qiagen Innovates with Digital PCR Assays for Ebolavirus Amid Legal Scrutiny
Qiagen NV (Ticker: QGEN) launches new digital PCR assays that target the Bundibugyo ebolavirus, a decisive step in strengthening its portfolio of infectious disease research tools. This launch not onl…
Deutsche Bank Upgrades Qiagen NV, Highlights Recovery Amid Market Volatility
Qiagen NV's Analyst Upgrades Signal Recovery Potential Amidst Market Volatility In recent developments, Deutsche Bank upgrades Qiagen NV to a 'buy' rating, a significant shift considering the company’…
Analyst Upgrade Reaffirms Qiagen's Potential for Recovery Amid Market Challenges
Strategic Upgrade Positions Qiagen for Recovery Amid Market Fluctuations Recent analyst activity highlights significant movements for Qiagen NV, particularly following an upgrade from Deutsche Bank th…